Cargando…
Pharmacodynamic Modelling of Biomarker Data in Oncology
The development of pharmacodynamic (PD) biomarkers in oncology has implications for design of clinical protocols from preclinical data and for predicting clinical outcomes from early clinical data. Two classes of biomarkers have received particular attention. Phosphoproteins in biopsy samples are ma...
Autor principal: | Jackson, Robert C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302113/ https://www.ncbi.nlm.nih.gov/pubmed/22523699 http://dx.doi.org/10.5402/2012/590626 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022) -
Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
por: Kirouac, D C, et al.
Publicado: (2013) -
Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
por: Bender, Brendan C, et al.
Publicado: (2015) -
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014) -
Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
por: Papachristos, Apostolos, et al.
Publicado: (2023)